Intranasal steroids prevent antigen-induced hyperresponsiveness of the nasal ocular response

Trial Profile

Intranasal steroids prevent antigen-induced hyperresponsiveness of the nasal ocular response

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 May 2013

At a glance

  • Drugs Fluticasone furoate (Primary)
  • Indications Seasonal allergic rhinitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Jun 2009 Corticosteroids identified as fluticasone furoate
    • 28 May 2008 Status changed from in progress to completed, as reported on clinicaltrials.gov
    • 20 Dec 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top